

eTable1. Baseline Patient Characteristics and Outcome Measures Among Included different-doses studies									
	Nakatsuka et al. (2016) R			Nakatsuka et al. (2016) P			Suzuki et al. (2019)		
	Cilostazol Dose (mg/day)			Cilostazol Dose (mg/day)			Cilostazol Dose (mg/day)		
	0	100-200	300	0	100-200	300	0	100-200	300
Study design	retrospective			prospective			retrospective		
No. (F/M)	36 (24/12)	39 (30/9)	12 (9/3)	5 (3/2)	23 (10/13)	10 (7/3)	49 (NS)	56 (NS)	51 (NS)
Mean age	65.6 ± 13.3	61.1 ± 12.9	65.4 ± 10.4	51.6 ± 8.1	65.5 ± 14.4	64.1 ± 12.3	NS	NS	NS
Delayed cerebral infarction	10	7	1	1	3	0	16	11	2
Shunt-dependent hydrocephalus	12	5	1	2	8	1	13	9	13
mRS (0-2) at discharge	17	24	8	3	6	6	24	31	25